282 vs. 233: Closing India's heart attack gap

I have opened more chests than I can count. In the early years of my career, the patient on my table was mostly sixty years and above. As early as 2010s, this began to change. I still remember the case of 28 year old Vishnu Yadav, who had an aneurysm emerging from his left ventricle. I remember this very clearly because his aneurysm or swelling was five times as big as his heart.Today, I routinely operate on men and women in their early forties. Some are in their thirties and twenties. This is not a statistic to me; every patient is a life I care about. I feel the wound every time I make an incision.So let me put the numbers plainly. India's age-standardized cardiovascular death rate stands at 282 per 100,000 people. The global average is 233. We are not catching up to the world's heart health; for some reason, we are falling further behind, even as our hospitals fill with technology the world's best centers would envy and we speak ad nauseum about big data and AI.This is the paradox I want you to sit with. In our best urban hospitals, we now have AI algorithms that can flag a heart attack risk years before symptoms appear. We have genetic panels that map a patient's inherited vulnerabilities down to specific gene variants. We have new-generation lipid-lowering drugs ( PCSK9 inhibitors and beyond) that can drive LDL cholesterol to levels we once thought biologically impossible. If technology alone could save hearts, India's urban elite should be the healthiest heart cohort on god’s green earth!They are not. And the reason is uncomfortable but simple: we have built a formidable arsenal for treating heart disease, while doing far too little to prevent the conditions that cause it. Chronic stress, sedentary work, diets filled with refined carbohydrates and trans fats, disrupted sleep, unchecked hypertension, and a genetic predisposition to insulin resistance are working on Indian bodies every single day, largely unopposed.A precision genetic test is of little use to a patient who then returns to sixteen-hour workdays and a plate of fried food eaten in a rush. And that too swallowed down in a distracted fashion with little or no chewing. Here is what forty years in operating theatres has taught me: the most powerful cardiac intervention I know is not a stent or a bypass graft. It is years, even decades, before either becomes necessary. And this is precisely where India now has an extraordinary, almost unrepeatable opportunity.We are, right now, building the health-tech and insurance infrastructure that could make India a global leader in cardiac prevention rather than a global leader in cardiac disease. Wearable devices that track heart rate variability and sleep quality are becoming affordable. Early imaging techniques (coronary calcium scoring, carotid intima-media thickness) can now detect atherosclerosis building silently, years before any chest pain occurs. Insurance companies are beginning to link premiums to preventive health metrics. Telemedicine reaches towns that many generations of surgeons never visited.The opportunity before us is to fuse these two strands: high technology and lifestyle medicine, into a single, coherent strategy, rather than treating them as separate worlds. A young executive should not merely receive a genetic risk score; she should receive, in the same visit, a concrete plan for sleep, movement, and stress management, tracked and reinforced by the very wearable on her wrist. A corporate wellness program should not stop at an annual health check-up; it should use that data to intervene before the heart attack, not annotate the file afterward.I have spent my career repairing the damage of delayed preventive measures. It would make me happy to spend the next decade doing less repair and more prevention. Not because cardiology has failed, but because it finally succeeded upstream in every home, where it matters the most.India has the tools. What remains is the will to use them before the operating table becomes necessary, not after. The gap between 282 and 233 is not a mystery. It is a choice we have not yet fully made.Dr Ramakanta Panda, World’s leading cardiac surgeon and Chairman, Asian Heart Institute, MumbaiGet the latest movie news, reviews, and celebrity updates. Download the TOI App.